From the 2020 Joint Annual Meeting (July 1, 2020)
Presented by Mariko Nakano, PhD
Why don’t we have preemptive pharmacogenetic (PGx) testing implemented at every clinic? The pharmacoeconomical benefit has been researched and the results indicate a reduction in the patient’s financial burden. Using the PGx testing for mental health as an example, this session will describe the various challenges of PGx testing implementation within general healthcare practices.
At the conclusion of this presentation, participants will be able to:
- Describe the financial benefit to perform Pharmacogenetic testing in mental health.
- Discuss the challenges of PGx testing; regulation, insurance policy, and scientific interpretation.
- Review the importance and clinical utilities of PGx testing,
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Administration/General will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.
LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.